In a filing, Axsome Therapeutics Inc revealed its Officer Herriot Tabuteau acquired Company’s shares for reported $5.06 million on Jan 06 ’26. In the deal valued at $171.88 per share,29,450 shares were bought.
Then, Herriot Tabuteau bought 78,703 shares, generating $13,496,777 in total proceeds.
Before that, Saad Mark E sold 37,577 shares. Axsome Therapeutics Inc shares valued at $6,206,969 were divested by the Director at a price of $165.18 per share. As a result of the transaction, Saad Mark E now holds 10,002 shares, worth roughly $1.72 million.
B. Riley Securities initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on October 01, 2025; the price target was $179. Oppenheimer started covering the stock on June 03, 2025. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 0.23% to $171.88. Over the last five days, the stock has gained 14.07%. Axsome Therapeutics Inc shares have risen nearly 96.84% since the year began. Nevertheless, the stocks have fallen -5.89% over the past one year. While a 52-week high of $184.40 was reached on 01/02/26, a 52-week low of $79.19 was recorded on 01/05/26.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 169.45, which if violated will result in even more drops to 167.03. On the upside, there is a resistance level at 175.15. A further resistance level may holdings at 178.43.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-12-15, dropping by -0.56 million shares to a total of 2.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 3.39 million shares. There was a decline of -19.68%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 07, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $200 price target.
